Key result
Aspirin use significantly reduced all-cause mortality (OR 0.894) in patients with congestive heart failure compared to no aspirin, without increasing heart failure hospitalizations.
Why the study?
There is no clear consensus on aspirin use in patients with CHF due to its reported interaction with other cardio-prudent medications.
Does aspirin reduce all-cause mortality and heart failure hospitalization in patients with congestive heart failure?
Meta-Analysis (n=64,550)
Does aspirin reduce all-cause mortality and heart failure hospitalization in patients with congestive heart failure?
Odds Ratio: 0.894 (95% CI 0.831–0.962)
p-value: p=0.003
Aspirin use is associated with a significant reduction in all-cause mortality among patients with congestive heart failure, though it does not significantly reduce heart failure hospitalizations overall.
Supports aspirin consideration in CHF for mortality reduction without HF hospitalization increase; extends meta-analytic evidence on net benefit.
BACKGROUND: There is no clear consensus on the use of aspirin (ASA) in patients with congestive heart failure (CHF) due to its reported interaction with other cardio-prudent medications. The aim was to evaluate the effect of ASA on all-cause mortality and the frequency of hospitalization for heart failure in patients with CHF using meta-analysis, as well as to study the potential variables interacting with this effect. METHODS: Eligible studies were identified via a PubMed search, the "related article" feature and a manual search of references. Studies were included if they had a study population with CHF of any etiology, compared ASA to no ASA or placebo, and reported one or both of the following outcomes: 1) all-cause mortality and 2) the frequency of hospitalization for heart failure. Data were extracted and verified. We used the inverse variance method in a random-effects model to combine effect sizes. RESULTS: A total of 14 studies with a combined study population of 64,550 patients were included in the final analysis. All-cause mortality was found to be significantly lower in patients who were taking ASA (P = 0.003). When examining the use of ASA, no significant difference was found in the frequency of hospitalization for heart failure. ASA use was demonstrated to be more beneficial against mortality in studies with a larger percentage of patients on nitrates (P = 0.008) and oral anticoagulants (P = 0.04). A significantly lower rate of hospitalization for heart failure was observed in patients who used oral anticoagulants and ASA concurrently (P = 0.02). CONCLUSIONS: ASA may have beneficial effects on mortality in patients with heart failure of all etiologies.
No takes yet. Share an insight, caveat, or question.
Jiwani et al. (2021) conducted a meta-analysis in Congestive heart failure (n=64,550). Aspirin vs. No aspirin or placebo was evaluated on All-cause mortality (OR 0.894, 95% CI 0.831 - 0.962, p=0.003). Aspirin use significantly reduced all-cause mortality (OR 0.894) in patients with congestive heart failure compared to no aspirin, without increasing heart failure hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: